BGM vs Jaguar Health
BGM and JAGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BGM and JAGX compare
Jaguar Health grew revenue faster over the last twelve months (136% versus 51.1% for BGM).
BGM scores higher on the StockData Score (9 against 3 for Jaguar Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BGM | JAGX |
|---|---|---|
| Size and price | ||
| Market cap | – | $2.2M |
| Share price | $8.01 | $0.420 |
| Change, 1 year | −97.1% | −100.0% |
| Change, 5 years | −98.3% | −100% |
| Beta (5Y) | 1.94 | – |
| Employees | 206 | 47 |
| StockData Score | ||
| Total score | 9 (better) | 3 |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 2 (better) | 0 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 0.1× |
| Growth | ||
| Revenue growth (TTM) | 51.1% | 136% (better) |
| Revenue growth, 5Y average | −5.4% | 4.2% (better) |
| Profitability | ||
| Gross margin | 16.6% | 82.3% (better) |
| Operating margin | −33.2% (better) | −93.1% |
| Net margin | −52.6% | – |
| FCF margin | −10.4% | – |
| Return on equity | −9.2% | – |
| Return on invested capital | −4.8% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −25.9× |
| Current ratio | 1.24 (better) | 0.69 |
| Altman Z-score | – | −18.45 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.00% | – |
| Held by insiders | 52.5% | 17.1% |
| Short interest, % of float | 0.00% | 4.7% |
Go deeper
- BGM stock overview
- BGM income statement
- BGM valuation and score
- JAGX stock overview
- JAGX income statement
- JAGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.